Back
Revvity, Inc. (RVTY)
Life Sciences Tools & ServicesRVTY · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$154.18
+1.33%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$2.07
ROE
3.2%
Gross margin
54.3%
Debt/Equity
0.47x
Revenue growth
7.0%
Revvity, Inc. — company intelligence
Earnings surprises
Q2 2026$1.41 vs $1.25 est+13.1%
Q1 2026$1.06 vs $1.04 est+2.3%
Q4 2025$1.70 vs $1.58 est+7.4%
Q3 2025$1.18 vs $1.16 est+1.7%
Analyst consensus · 25 analysts
13 Buy12 Hold0 Sell
Updated Oct 10, 2026
Insider activity · 90 days
0 buys4 sellsnet -9,130 shares
Gonzales AnitaSell 84 · Oct 1, 2026
Krakowiak MaxwellSell 1,631 · Sep 21, 2026
Vohra Tajinder SSell 7,330 · Sep 16, 2026
Recent SEC filings
4 — Insider transaction reportOct 2, 2026
4 — Insider transaction reportSep 23, 2026
4 — Insider transaction reportSep 18, 2026
Latest news
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript — SeekingAlpha · Sep 9, 2026
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery — Yahoo · Sep 9, 2026
UBS Assumes Revvity at Neutral, Raises Price Target to $140 — Benzinga · Sep 9, 2026
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition — Benzinga · Sep 9, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.